

Lisbeth Juhler Andersen

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6432930/lisbeth-juhler-andersen-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19
papers

518
citations

11
h-index

19
g-index

19
ext. papers

625
ext. citations

2.6
avg, IF

3.1
L-index

#	Paper	IF	Citations
19	Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer. <i>Radiotherapy and Oncology</i> , 2014 , 113, 310-6	5.3	121
18	Evaluation of comorbidity in 9388 head and neck cancer patients: a national cohort study from the DAHANCA database. <i>Radiotherapy and Oncology</i> , 2014 , 110, 91-7	5.3	71
17	The impact of comorbidity on outcome in 12 623 Danish head and neck cancer patients: a population based study from the DAHANCA database. <i>Acta Oncologica</i> , 2013 , 52, 285-93	3.2	70
16	Salivary adenoid cystic carcinoma in Denmark 1990-2005: Outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA). <i>Oral Oncology</i> , 2015 , 51, 1138-42	4.4	55
15	The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2015 , 117, 91-8	5.3	44
14	Consequences of introducing geometric GTV to CTV margin expansion in DAHANCA contouring guidelines for head and neck radiotherapy. <i>Radiotherapy and Oncology</i> , 2018 , 126, 43-47	5.3	28
13	Pattern of failure in 5001 patients treated for glottic squamous cell carcinoma with curative intent - A population based study from the DAHANCA group. <i>Radiotherapy and Oncology</i> , 2016 , 118, 257-66	5.3	25
12	Quality assurance of radiation therapy for head and neck cancer patients treated in DAHANCA 10 randomized trial. <i>Acta Oncologica</i> , 2015 , 54, 1669-73	3.2	19
11	DAHANCA 10 - Effect of darbeopetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group. <i>Radiotherapy and Oncology</i> , 2018 , 127, 12-19	5.3	16
10	Polymorphous low-grade adenocarcinoma: A Danish national study. <i>Oral Oncology</i> , 2016 , 55, 6-10	4.4	15
9	Salivary duct carcinoma: a Danish national study. <i>Journal of Oral Pathology and Medicine</i> , 2016 , 45, 664-671	3.3	14
8	Does age affect prognosis in salivary gland carcinoma patients? A national Danish study. <i>Acta Oncologica</i> , 2016 , 55 Suppl 1, 19-22	3.2	11
7	Incidence of and survival after glottic squamous cell carcinoma in Denmark from 1971 to 2011-A report from the Danish Head and Neck Cancer Group. <i>European Journal of Cancer</i> , 2016 , 59, 46-56	7.5	10
6	Oncocytic carcinoma of the salivary glands: A Danish national study. <i>Auris Nasus Larynx</i> , 2018 , 45, 825-830	0.2	6
5	DAHANCA 9 - a randomized multicenter study to compare accelerated normo-fractionated radiotherapy with accelerated hyperfractionated radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC). <i>Acta Oncologica</i> , 2019 , 58, 1502-1505	3.2	5
4	Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial. <i>Acta Oncologica</i> , 2018 , 57, 1159-1164	3.2	5
3	Correlation between pretreatment FDG-PET biological target volume and location of T-site failure after definitive radiation therapy for head and neck cancers. <i>Acta Oncologica</i> , 2015 , 54, 1682-5	3.2	2

- 2 Subglottic squamous cell carcinoma in Denmark 1971-2015 - a national population-based cohort study from DAHANCA, the Danish Head and Neck Cancer group. *Acta Oncologica*, **2019**, 58, 1509-1513 3.2 1
- 1 Metastatic or locally advanced colorectal cancer treated with 5-fluorouracil and low dose leuovorin. *Acta Oncologica*, **1994**, 33, 931-4 3.2